

Quote | Chart

All CNBC | News | Video

Enter Symbol

GO

Symbol
Lookup

Enter Keyword

SEARCH

investools

Welcome, Guest

HOME NEWS MARKETS EARNINGS INVESTING VIDEO CNBC TV CNBC PLUS CONTEST

Register | Sign In

U.S. | ASIA-PACIFIC | EUROPE | ENERGY | GREEN | POLITICS | TECHNOLOGY | BLOGS | LATEST NEWS | SLIDESHOWS | SPECIAL REPORTS | CONTEST

New Biopharma Company Appian Labs, LLC Provides Drug Design and Delivery Solutions Award-Winning Scientific Team Is Led by Drug Delivery Pioneer Nicholas Peppas, Sc.D.

| 17 Jun 2008 | 08:05 AM ET

Font size: [A](#) [A](#)

AUSTIN, Texas, Jun 17, 2008 (BUSINESS WIRE) -- Appian Labs, LLC, a biopharmaceutical company specializing in advanced therapeutic design, announced today its launch as a new company focused on providing comprehensive and strategic drug delivery and design solutions for pharmaceutical and other bioactives companies worldwide. The company provides solutions for a number of drug delivery problems, including poor bioavailability or solubility, dose timing, toxicity and many others. Appian Labs is funded and managed by venture firm Emergent Technologies, Inc. (ETI).

Appian's laboratory is led by Chief Scientist Nicholas Peppas, Sc.D., a pioneer in the field of drug delivery and controlled release chemistry over the last three decades. Dr. Peppas has published more than 1,050 peer-reviewed articles and 33 books, covering drug delivery, hydrogels, and related controlled release.

He has made life-changing contributions to drug delivery and biomaterials applications using his recognized expertise in biomedical engineering and polymer chemistry.

Apily named for the great, innovative feat of human engineering, the Appian Way, the leading delivery route of the ancient world, Appian Labs' industry-leading scientist laid the foundation of the science and mathematical formulas used broadly in the modern drug delivery industry today. Now, employing the latest innovations in drug design and delivery, Appian Labs' technologies will be utilized to develop next-generation drug formulations for safer and improved healthcare.

Drug Delivery by Design Brian Windsor, Ph.D., President of Appian Labs, said, "Building on the drug delivery leadership of our scientific team, we can design delivery solutions tailored to pharma companies' drugs and that improve bioavailability, dosing, or timing of a drug. Our breadth of expertise and technologies enables us to match virtually any kinetic profile desired." The company's first marketing initiative to potential pharmaceutical partners is an invitation to 'Draw your own profile' and Appian Labs will design a custom drug delivery system to match.

Windsor added, "Having worked with pharmaceutical companies for several decades to solve drug delivery problems, our scientific team knows both the common needs and the far-reaching goals of drug manufacturers." Nicolas Peppas, Sc.D.

Dr. Nicolas Peppas has received numerous awards for his multidisciplinary research in drug delivery, biomedical engineering and polymer chemistry.

Recognized internationally as a leading scientist, he is a member of both the National Academy of Engineering and the French Academy of Pharmacy. In addition to serving as Chief Scientist of Appian Labs, Peppas will remain as the Fletcher Stuckey Pratt Chair in Engineering in the Departments of Chemical and Biomedical Engineering and Professor in the College of Pharmacy at the University of Texas at Austin.

About Appian Labs Appian Labs, LLC is a biopharmaceutical company specializing in advanced therapeutic design. The company is focused on providing drug delivery and design solutions for biotech, pharmaceutical and life science companies worldwide.

Appian Labs provides solutions for a number of drug delivery problems, including poor bioavailability or solubility, dose timing, toxicity and many others.

Founded on the pioneering work in drug delivery systems of Chief Scientist Dr.

Nicholas Peppas, the company designs tailor-made solutions to current drug delivery problems as well as innovative new formulations for the next generation of pharmaceuticals. Appian Labs is funded and managed by life sciences venture firm, Emergent Technologies, Inc. (ETI). For more information, visit the company website www.appianlabs.com About Emergent Technologies, Inc.

Emergent Technologies Inc. (ETI), founded in 1989 by Thomas A. Harlan, is a unique life sciences venture firm that forms and manages companies and funds that commercialize groundbreaking institutional and university-based technologies. ETI is a turnkey solution for converting university science into high return ventures. ETI works with regional economic development groups and universities to capitalize on what the firm describes as invention capital. In addition to the traditional venture capital approach of raising and investing funds, ETI drives the selection and expansion of each technology assets unique to their region. ETI is pioneering a unique business approach to investment in intellectual property, the key asset to most technology-based start-up companies. For more information, visit the company website www.etbio.com SOURCE: Emergent Technologies, Inc.

CONTACT: Nsight Public Relations Sandra Oak, 321-591-1508 soak@nsightpr.com Copyright Business Wire 2008 -0- KEYWORD: United States

North America

Texas INDUSTRY KEYWORD: Health

Biotechnology

Pharmaceutical

ADVERTISEMENT

MORE HEADLINES

Markets | Economy | Companies



EU Leaders Worried by Inflation, See No Quick Fix

Moody's Cuts MBIA, Ambac Top Insurance Ratings
Sumitomo Mitsui May Invest \$926 Million in Barclays
Asian Markets See-Saw as Stocks React to Oil's Tumble
Oil Slips to \$131 on Chinese Fuel Price Hike
CNBC Top Videos of the Day: Cramer Talks Banks
BoFA To Acquire Countrywide by July 1: Source
Washington Mutual Cuts Another 1,200 Jobs
Fed Talks Up Interest Rates —And Housing Gets Hit
Pimco's Gross: Regional Banks Not Too Big to Fail

LATEST FROM OUR BLOGS

More

Petrohawk CEO: Natural Gas Is Happening Now

Sell Block: Goldman's Bank Hit List
Lightning Round OT: Visa, Mercadolibre and More
Lightning Round: Sears, Hershey, Qualcomm and More
Does Clean Coal Exist?
Your First Move For Friday June 20th
Web Extra: Is Solar Sustainable?
Fast & Furious Trades: Winnebago, Sprint...
'70's Fun Trade
Pops & Drops: Petrochina, AIG...

Tools:  [Print](#)  [Email](#)  [Del.icio.us](#)  [Digg It](#)

[HOME](#) | [NEWS](#) | [MARKETS](#) | [EARNINGS](#) | [INVESTING](#) | [VIDEO](#) | [CNBC TV](#) | [CNBC PLUS](#) | [CNBC HD+](#)
[About CNBC](#) | [Site Map](#) | [Privacy Policy](#) | [Terms of Service](#) | [Advertise](#) | [Help](#) | [Feedback](#) | [Video Reprints](#)
Partners: [AOL Money](#) | [BloggingStocks.com](#)

(c) 2008 CNBC, Inc. All Rights Reserved



RT Data is a real-time snapshot *Data is delayed at least 15 minutes
Global Business and Financial News, Stock Quotes, and Market Data and Analysis